Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of LW231 in Patients With Chronic Hepatitis B: Evaluation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy With Multiple-Dose, Dose-Escalation, and Combination With Nucleos(t)Ide Analogs (NUC)

NCT07179575 is registered in ClinicalTrials.gov with Shanghai Longwood Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07179575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07179575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of LW231 in Patients With Chronic Hepatitis B: Evaluation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy With Multiple-Dose, Dose-Escalation, and Combination With Nucleos(t)Ide Analogs (NUC)
Lead sponsor
Shanghai Longwood Biopharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 11, 2025
Completion date
November 30, 2027
Enrollment
270 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hbv infection